Consider the following points:
 

• About 20 percent of healthy adults, in a period of 24 hours worldwide, are likely to experience frequent or multiple types of premature ventricular heartbeats.
• More than 850,000 Americans are hospitalized following complaints of arrhythmia, almost every year.

 
Critical health statistics have turned various eyes toward developments in the cardiac healthcare space, paving the way for the introduction of cardiac arrhythmia monitoring devices. These devices in use today are transforming to raise the bar beyond monitoring and managing cardiac issues. Use of these devices has substantially increased for a while now, due to rising life expectancy and ongoing technological developments that have extended their abilities and scopes.
 
An aging world population, in tandem with the emergence of advanced cardiac management, monitoring, and treatment options for heart arrhythmias is impelling the growth spectrum of the global cardiac arrhythmia monitoring device market. It has been estimated the overall market is set to reach an annual valuation of $9 billion by 2026.
 
This is courtesy of the latest developments and trends in the field. Moreover, phenomenal R&D contributions from leading biotech firms in the cardiac management business are also helping to raise the escalating graph of the cardiac arrhythmia device industry.
 
Recently, researchers at the University of Washington announced developing a contactless way to monitor irregular heartbeats, even via ordinary smart speakers and AI-based systems. According to reports, the novel monitoring system is powered by an AI solely based on SONAR technology to trace vibrations caused by chest wall movements.
 
Once deployed, the technology is expected to enhance the way healthcare experts conduct telemedicine appointments by offering data that would otherwise require healthcare hardware, wearables, or an in-person checkup. A main motive behind this revolutionary breakthrough, as stated by the research team, was to carve out a way to make use of subtle devices that people already have to edge health and cardiology monitoring into the near future.
 
In yet another instance, a leading company engaged in activity tracking through smart wearables, Fitbit, had in May 2020, announced the launch of its new atrial fibrillation research study. It aimed to enroll nearly 200,000 to 250,000 device owners for passive, continuous monitoring of heart rates.
 
Named the Fitbit Heart Study, the activity was anticipated to detect the heart rates via the devices’ PPG (photoplethysmography) sensors. A patent algorithm will interpret the reading received and flag potential irregularities for follow up. This study would also allow medical professionals to see how well the model of healthcare works for screening atrial fibrillation.
 
Some of the latest developments in cardiac arrythmia monitoring devices market space likely to shape up the industry growth in the upcoming years have been outlined below:
 
Abbott’s Implantable Cardiac Monitor
In 2019, a pioneer in medical device production and commercialization, Abbott Laboratories launched a new, smarter heart monitor for better arrhythmia analysis. This novel innovation is good news for people highly susceptible to irregular heartbeats. Now with a CE mark and FDA clearance, the next-gen Confirm Rx insertable cardiac monitor combines smartphone connectivity and remote monitoring to detect unpredictable heart rhythm problems for effective, accurate, and fast diagnosis.
 
Along with diagnosing irregular heartbeats, the device’s new detection technology is also likely to reduce false detection rate by 97 percent, avoiding alerts sent to physicians of irregular heartbeats that might not actually be a signal of cardiac arrythmia.
 
Zio system by iRhythm
In October 2019, digital healthcare company iRhythm announced its Zio service in the United Kingdom to support identification and clinical monitoring of cardiac arrhythmias like atrial fibrillation. The Zio system, a tiny wearable heart monitor that attaches to the patient’s chest for up to 14 days, offers detailed and accurate monitoring of heartbeats as patients go about their daily activities including sleeping, showering, and exercising.
 
One of the intrinsic features that makes the product stand a level apart in the health monitoring domain is deployment of artificial intelligence. In addition to this, the Zio service also seeks to streamline the patient diagnostic journey while ensuring both the patients and clinicians get answers they need for the right treatment path.
 
In fact, it is essential to mention that the UK’s National Institute for Health and Care Excellence had in December 2020 recommended the use of Zio XT service for those with cardiac arrhythmias, who would be benefitted by ECG monitoring for more than 24 hours. That said, the regulatory recommendation of Zio XT paves the way for other producers to incorporate deep learning into their cardiac monitors to augment future devices.
 
Alongside the product diversifications, potential mergers and acquisition are also likely to revamp the business sphere of the cardiac arrhythmia monitoring device market.
 
For instance, a universal leader in AI cardiology diagnostics, Cardiologs, announced entering an exclusive distribution agreement with MicroPort CRM to reselling its cloud analysis solution for Holter ECGs in France. According to official sources, the ECG Holter pact is expected to mark the official launch of Cardiologs AI-based cloud technology biz operations in Europe to monitor cardiac rhythm disorders.
 
With cardiac issues still persisting across the globe, the need for proper cardiac arrhythmia monitoring solutions and devices is poised to escalate multifold in the years to come.